Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A8J8YBS4 (A0A8J8YBS4_MACMU) Macaca mulatta (Rhesus macaque)

Tyrosine-protein kinase UniProtKBInterProInteractive Modelling

659 aa; Sequence (Fasta) ; 10 identical sequences: Homo sapiens: Q06187; Pan troglodytes: A0A2I3RVY9; Pan paniscus: A0A2R9BPC2; Gorilla gorilla gorilla: G3SKC9; Mandrillus leucophaeus: A0A2K6A443; Macaca nemestrina: A0A2K6CUV5; Macaca mulatta: F6V0I6; Macaca fascicularis: A0A2K5VDZ2; Nomascus leucogenys: G1R7I9; Rhinopithecus roxellana: A0A2K6PTH4

Available Structures

129 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihyd… Heteromer
Q06187;
385-658
N42;
Assess
Structure of cIAP1, BTK and BCCov Heteromer
Q06187; Q13490;
392-659
TOO;ZN;
Assess
Ternary complex structure - BTK cIAP compound 15 Heteromer
Q06187; Q13490;
393-657
ZN;TKY;
Assess
Ternary complex structure - BTK cIAP compound 17 Heteromer
Q06187; Q13490;
396-656
TL7;ZN;
Assess
Crystal structure of human Btk SH2 domain bound to rF10 repebody Heteromer
Q06187;
276-379
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4homo-4-mer2-170
ZN;4IP;
Assess
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATEhomo-4-mer2-170
ZN;4IP;
Assess
The structure of human BTK kinase domain in complex with a covalent inhibitorhomo-2-mer394-656
GYL;
Assess
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO …homo-2-mer396-656
6MV;
Assess
Crystal structure of Bruton's tyrosine kinase domainhomo-2-mer397-654
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28Chomo-2-mer2-170
ZN;NA;
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGANDmonomer389-659
GJD;
Assess
BTK1 SOAKED WITH IBRUTINIB-Revmonomer389-659
1E8;DMS;
Assess
CRYSTAL STRUCTURE OF BTK with CNX 774monomer389-659
7G8;
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer389-659
GJG;
Assess
Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-…monomer389-659
83P;EDO;PEG;
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer389-659
X9M;
Assess
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxy…monomer389-659
KLM;EDO;
Assess
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinibmonomer389-659
CL;MZJ;
Assess
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059monomer389-659
7GB;DMS;
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer389-659
GJ7;DMS;
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer389-659
4US;DMS;EDO;
Assess
Bruton's tyrosine kinase (BTK) with GDC-0853monomer389-659
9AJ;EDO;SO4;
Assess
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinasemonomer389-659
IMD;IPA;EDO;4L6;
Assess
BTK1 SOAKED WITH COMPOUND 25monomer389-659
X9V;DMS;
Assess
BTK in complex with 18Amonomer389-659
2IE;
Assess
Discovery of affinity-based probes for Btk occupancy assaymonomer389-659
KHD;
Assess
Crystal structure of ARQ 531 in complex with the kinase domain of BTKmonomer389-658
HRA;IMD;EDO;
Assess
Crystal structure of the noncovalently bonded complex of rilzabrutinib with BTKmonomer389-658
R1L;DMS;PEG;EDO;SO4;ACT;
Assess
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
IMD;PGO;0BQ;EDO;
Assess
BTK1 SOAKED WITH COMPOUND 30monomer390-659
DMS;X9Y;
Assess
BTK in complex with 25Amonomer390-659
2IJ;DMS;
Assess
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
IMD;EDO;DMS;0UW;
Assess
Bruton's tyrosine kinase in complex with 3-{[4-(1-acetylpiperidin-4-yl)phenyl]amino}-5-[(3R)-3-(3-m…monomer389-658
WKC;EDO;PD;CL;
Assess
Fragment-Based Discovery of a Novel Bruton's Tyrosine Kinase Inhibitormonomer389-658
IMD;PGO;DMS;0GW;
Assess
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragmentmonomer389-658
IMD;IPA;DMS;4RU;
Assess
Fragment-Based Drug Design of a Novel, Covalent Bruton's Tyrosine Kinase Inhibitormonomer389-658
IMD;0CI;DMS;
Assess
Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[…monomer389-658
UP9;EDO;CL;IOD;
Assess
Bruton's tyrosine kinase in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phenyl]amino}pyra…monomer389-658
YXJ;EDO;CL;
Assess
Bruton's tyrosine kinase (BTK) with compound 13monomer389-658
UB6;PGE;
Assess
Bruton's tyrosine kinase in complex with N-[(2R)-1-[(3R)-3-(methylcarbamoyl)-1H,2H,3H,4H,9H-pyrido[…monomer389-658
UQX;NA;CL;SO4;EDO;
Assess
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnolinemonomer389-658
IMD;IPA;DMS;4RV;
Assess
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(…monomer391-659
04K;
Assess
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(…monomer391-659
04L;
Assess
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-…monomer391-659
LHL;
Assess
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-met…monomer391-659
03C;
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITORmonomer392-659
GJJ;DMS;
Assess
BTK In Complex With Inhibitormonomer391-658
LTJ;
Assess
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-…monomer391-658
027;
Assess
BTK-inhibitor co-structuremonomer392-659
5WH;5WE;
Assess
Co-structure of BTK kinase domain with L-005085737 inhibitormonomer392-659
ULV;5WE;
Assess
Crystal structure of the covalently bonded complex of rilzabrutinib with BTKmonomer392-659
R1L;SO4;
Assess
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitormonomer391-658
4C9;NA;EDO;SO4;CL;
Assess
BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazo…monomer392-659
KLP;SO4;
Assess
Crystal structure of BTK kinase domain complexed with R406monomer391-658
585;
Assess
Co-crystal structure of BTK kinase domain with Zanubrutinibmonomer393-659
BA0;IMD;
Assess
Bruton's tyrosine kinase in complex with compound 34monomer393-659
ZB9;DMS;PEG;
Assess
Bruton's tyrosine kinase in complex with compound 5monomer392-658
DMS;RQS;
Assess
Bruton's tyrosine kinase in complex with compound 45monomer392-658
0B9;
Assess
Bruton's tyrosine kinase in complex with an orthosteric inhibitormonomer392-658
DMS;Y8H;
Assess
Bruton's tyrosine kinase in complex with compound 6monomer393-659
DMS;DTT;S5M;
Assess
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containi…monomer392-658
B43;
Assess
Bruton's tyrosine kinase L528W mutant in complex with 5-(piperidin-1-yl)-3-{[4-(piperidin-4-yl)phen…monomer392-658
YXJ;EDO;
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTEREDmonomer392-658
X9J;DMS;
Assess
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechan…monomer392-658
1N1;
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGANDmonomer393-659
GJA;
Assess
BTK1 COCRYSTALLIZED WITH IBRUTINIBmonomer394-659
8E8;
Assess
BTK1 IN COMPLEX WITH CC 292monomer392-657
7G9;
Assess
Co-structure of BTK kinase domain with L-005298385 inhibitormonomer394-659
UM4;EDO;BTB;
Assess
BTK1 SOAKED WITH COMPOUND 26monomer394-659
X9P;DMS;
Assess
Bruton's tyrosine kinase in complex with compound 1monomer393-658
S9A;DMS;
Assess
Bruton's tyrosine kinase in complex with compound 21monomer393-658
0BG;DMS;
Assess
Bruton's tyrosine kinase in complex with compound 23monomer393-658
YD7;DMS;
Assess
BTK IN COMPLEX WITH GDC-0834monomer394-659
2VL;EDO;GOL;
Assess
BTK in complex with LOU064, a potent and highly selective covalent inhibitormonomer393-658
NA;N6Z;
Assess
BTK complex with compound 12monomer393-657
SO4;DXM;FPZ;GOL;
Assess
Bruton's tyrosine kinase in complex with compound 51monomer394-658
YDA;DTT;ACT;
Assess
Brutons tyrosine kinase in complex with compound 50.monomer395-659
L9S;EDO;
Assess
Structure of BTK with RN486monomer394-658
7G6;
Assess
Co-structure of BTK kinase domain with L-005191930 inhibitormonomer395-659
ULY;5WE;
Assess
BTK1 SOAKED WITH COMPOUND 24monomer395-659
X9S;DMS;
Assess
Bruton's tyrosine kinase in complex with compound 65monomer394-658
0B0;
Assess
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-ca…monomer394-658
2V1;
Assess
Bruton's tyrosine kinase in complex with an orthosteric inhibitormonomer395-659
DMS;Y8C;
Assess
Crystal structure of the human BTK kinase domainmonomer394-658
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23monomer394-657
SO4;GOL;PG0;3YO;
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9monomer394-657
SO4;GOL;PG0;6XL;
Assess
Co-crystal structure of BTK kinase domain with inhibitormonomer395-658
IS4;EDO;
Assess
Crystal structure of BTK kinase domain in complex with pirtobrutinibmonomer395-658
Y7W;SO4;GOL;BTB;
Assess
Bruton's tyrosine kinase (BTK) with compound G-744monomer394-657
SO4;GOL;PG0;9B1;
Assess
BTK kinase domain with inhibitor 1monomer395-658
5WF;5WE;CL;
Assess
BTK1 COCRYSTALLIZED WITH RN983monomer395-658
7G7;
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer396-658
GMQ;
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethy…monomer396-658
3OV;DMS;
Assess
BTK complex with compound 13monomer395-657
SO4;DY4;GOL;
Assess
Crystal structure of BTK C481S kinase domain in complex with pirtobrutinibmonomer395-657
Y7W;SO4;GOL;BTB;
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-…monomer396-658
GMW;
Assess
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fl…monomer396-658
73T;
Assess
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-…monomer396-658
2V2;DMS;
Assess
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-…monomer396-658
481;DMS;
Assess
BTK Fluorocyclopropyl amide inhibitor, Compound 25monomer395-657
V1G;SO4;
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815monomer395-657
SO4;BXM;
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625monomer394-656
GOL;SO4;BXJ;
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…monomer396-658
3OU;DMS;
Assess
BTK complex with compound 7monomer395-657
SO4;DTJ;GOL;
Assess
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1…monomer396-658
2V3;DMS;
Assess
BTK complex with compound 10monomer395-657
SO4;DVJ;
Assess
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinibmonomer394-656
1N1;
Assess
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperaz…monomer396-658
BNB;
Assess
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-…monomer396-658
3P0;
Assess
BTK complex with compound 11monomer396-657
SO4;DVD;
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746monomer395-656
SO4;BME;746;
Assess
BTK in complex with an inhibitormonomer395-656
L0Z;
Assess
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834monomer396-657
SO4;2VL;
Assess
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert…monomer396-657
2P5;
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…monomer396-657
4UQ;
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2emonomer395-655
9M3;
Assess
The PH domain of Bruton's tyrosine kinase mutant R28Cmonomer2-169
MG;ZN;
Assess
Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer2-169
MG;72V;ZN;
Assess
Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…monomer2-169
3IS;ZN;MG;
Assess
Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Br…monomer2-169
Q1B;MG;ZN;
Assess
Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's t…monomer2-169
ZN;MG;
Assess
The PH domain of Bruton's tyrosine kinase mutant R28Cmonomer2-168
NXT;MG;ZN;
Assess
Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosi…monomer2-168
NYQ;ZN;MG;
Assess
Crystal structure of PH domain of Bruton's tyrosine kinasemonomer2-168
ZN;4PT;
Assess
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinasemonomer270-387
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURESmonomer211-275
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTUREmonomer211-275
Assess
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structuresmonomer216-273
Assess

7 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8gmb.1.Amonomer0.74214-659
95.90
Assess
8xn8.1.Amonomer0.71217-656
MG;38.71
Assess
1y57.1.Amonomer0.69216-656
38.62
Assess
1opl.2.Amonomer0.69275-657
39.82
Assess
1k9a.1.Amonomer0.68214-657
37.30
Assess
4y93.1.Amonomer0.611-658
ZN;95.96
Assess
8s93.1.Amonomer0.591-659
ZN;92.34
Assess